Kamis, 02 Oktober 2014

Topic penelitian yang dapat anda gunakan untuk judul tesis atau disertasi S3



Hubungi sekarang juga - Kami mengerjakan tugas kuliah kedokteran , makalah, paper, proposal skripsi, tugas akhir, dijamin orisinil dan otentik.  0812 1944 9060

Jurnal yang sering digunakan untuk penelitian kedokteran:
             Cancer
             Nutrition & Cancer
             Journal of Clinical Oncology
             Journal of the National Cancer Institute
             Cancer Research
             Integrative Cancer Therapies
             American Journal of Clinical Nutrition
             Alternative Medicine Review
             International Journal of Cancer
             Clinical Pearls
             Anticancer Research
             Townsend Letter for Doctors & Their Patients

WEB RESOURCES
             www.oncanp.org
             www.aicr.org
             www.lifeovercancer.com
             www.cancerfacts.com
             www.nci.nih.gov
             www.cancernet.nci.nih.gov/clinpdq
             www.cancer.org      American Cancer Society  1-800-ACS-2345
             www.cdc.gov.org/cancer
             www.bccancer.bc.ca
             www.y-me.org
             www.asco.org
             www.Medscape.com  - oncology database
             www.inspirehealth.ca
             www.denvernaturopathic.com
             www.camresearch.net
             www.ncbi.nlm.nih.gov/PubMed/ 
             www.oncologystat.com 
             www.epec.net
             www.lifeovercancer.com

Topic penelitian yang  dapat anda gunakan untuk judul tesis atau disertasi S3:



Sulforaphane Absorption and Excretion Following Ingestion of a Semi-Purified Broccoli Powder Rich in Glucoraphanin and Broccoli Sprouts in Healthy Men, Cramer, & Jeffery, Nutr. Cancer 2011; 63 (2): 196 - 201.

Induction of Growth Arrest and Apoptosis in Human Breast Cancer Cells by 3,3-Diindolylmethane is Associated with Induction and Nuclear Localization of p27/kip, Wang, Yu, Rahman, et al.,  Mol. Cancer  Ther. 2008; 7: 341-349.


LOW-DOSE NALTREXONE
Enhancement of Natural Cytotoxicity by Beta-Endorphin, Matthew, Froelich, Sibbitt, et al., J. Immunol. 1983; 130:1658-1662.
Naltrexone Prolongs the Survival Time of Mice Treated with Neuroblastoma, Zagon & McLaughlin, Life Sci. 1981; 28: 1095-1102.
Naltrexone Modulates Tumor Response in Mice with Neuroblastoma, Zagon & McLaughlin, Science 1983; 221: 671-673.
Inhibition of Human Colon Cancer by Intermittent Opioid Receptor Blockade with Naltrexone, Hytrek, McLaughlin, Lang & Zagon, Cancer Letters 1996; 101 (2): 159-164.
Opioid Growth Factor ([Met5]Enkephalin) Prevents the Incidence and Retards the Growth of Human Colon Cancer, Zagon, Hytrek, Lang, et al.,  Amer. J. Physiol. 1996;  271 (3 Pt 2): R780-R786.
Opioid Antagonists Inhibit the Growth of Metastatic Murine Neuroblastoma, Zagon & McLaughlin, Cancer Letters  1983; 21: 89-94.
Duration of Opiate Receptor Blockade Determines Tumorigenic Response in Mice with Neuroblastoma: A Role for Endogenous Opioid Systems in Cancer, Zagon & McLaughlin,  Life Sci. 1984; 35: 409-416.
Opioid Antagonist Modulation of Murine Neuroblastoma: A Profile of Cell Proliferation and Opioid Peptides and Receptors, Zagon & McLaughlin, Brain Res. 1989; 480: 16-28.
Opioid Growth Factor (OGF) [Metenkephalin] Inhibits Human Pancreatic Cancer Transplanted into Nude Mice, Zagon, Hytrek, Smith & McLaughlin, Cancer Letters 1997; 112 (2): 167-175.
Neuro-immunotherapy of Untreatable Metastatic Solid Tumors with Subcutaneous Low-dose Interleukin-2, Melatonin and Naltrexone: Modulation of Interleukin-2-induced Anti-tumor Immunity by Blocking the Opioid System, Lissoni, Malugani, Malysheva, et al., Neuroendocrinol. Lett. 2002; 23 (4): 341-344.

 A New Neuro-immunotherapeutic Strategy of Subcutaneous Low-dose Interleukin-2 plus the Long-acting Opioid Antagonist Naltrexone in Metastatic Cancer Patients Progressing on Interleukin-2 Alone, Lissoni, Malugani, Bordin, et al., Neuroendocrinol. Lett. 2002; 23 (3): 255-258.

Opioid Growth Factor Regulates the Cell Cycle of Human Neoplasias, Zagon, Roesener, Verderame, et al., Int. J. Oncol. 2000; 17 (5): 1053-1061.

Reversal of Signs and Symptoms of a B-cell Lymphoma in a Patient Using only Low-dose Naltrexone, Integr. Cancer Ther. 2007; 6 (3): 293-296.

The Long-Term Survival of a Patient with Pancreatic Cancer with Metastases to the Liver After Treatment with the Intravenous Alpha-Lipoic Acid/Low-dose Naltrexone Protocol, Berkson, Rubin & Berkson, Integr. Cancer Ther. 2006; 5 (1): 83-89.

Revisiting the ALA/N (Alpha Lipoic Acid/Low Dose Naltrexone) Protocol for People with Metastasic and Non-Metastatic Pancreatic Cancer; A Report of 3 New Cases, Berkson, Rubin & Berkson, Integr. Cancer Ther. 2009; (4): 416-422.

Methylnaltrexone Inhibits Opiate and VEGF-induced Angiogenesis: Role of Receptor Transactivation, Singleton, Lingen, Fekete, et al., Microvasc. Res. 2006; 72 (1-2): 3-11.

Effect of Peri-Operative Opioids on Cancer Recurrence: A Hypothesis; Singleton & Moss, Future Oncol.  2010; 6 (8): 1237-1242.

Attenuation of the Tumor-promoting Effect of Surgery by Spinal Blockade in Rats, Ben-Eliyahu, Bar-Yosef, et al., Anesthesiology  2001; 94: 1066–1073.
Combined Spinal and General Anesthesia Attenuates Liver Metastasis by Preserving TH1/TH2 Cytokine Balance, Wada, Seki, Takahashi, et al., Anesthesiology 2007; 106: 499–506.
Morphine Stimulates Angiogenesis by Activating Pro-Angiogenic and Survival-Promoting Signaling and Promotes Breast Tumor Growth, Gupta, Kshirsagar, Chang, et al., Cancer Res. 2002; 62: 4491–4498.

Morphine Stimulates VEGF-like Signaling in Mouse Retinal Endothelial Cells, Chen, Farooqui & Gupta, Curr. Neurovasc. Res. 2006; 3: 171–180.
Naloxone Acts as an Antagonist of Estrogen Receptor in MCF7 Cancer Cells, Farooqui, Stephenson, Geng Zhen, et al.,  Mol. Cancer Therap. 2006; 5: 611–620.
Methylnaltrexone Inhibits EGF- and IGF-Induced Human Bronchioloalveolar Carcinoma Proliferation and Migration, Lennon, Mambetsariev, Garcia, et al., Mol. Cancer Ther. 2009; 8: C78–C78.
The (Mu) µ-Opioid Receptor Regulates Lewis Lung Carcinoma Tumor Growth and Metastasis, Mathew, Lennon, Siegler, et al., Mol. Cancer Ther. 2009; 8: C79–79C.


MELATONIN

The Therapeutic Application of Melatonin in Supportive Care and Palliative Medicine, Mahmoud, Sarhill & Mazurczak, Am. J. Hosp. Palliat. Care 2005; 22: 295-309.

Melatonin – Monograph, Alt. Med. Rev. 2005; Vol. 10, No. 4: 326-336.

Melatonin Provokes Cell Death in Human B-Lymphoma Cells by Mitochondria-Dependent Apoptotic Pathway Activation, Trubiani, Recchioni, Moroni, et al., J. Pineal Res. 2005; 39 (4): 425-431.

Melatonin Induces Apoptosis in Human Neuroblastoma Cancer Cells, Garcia-Santos, Antolin, Herrara, et al., J. Pineal Res. 2006; 41 (2): 130-135.

Increased Survival Time in Brain Glioblastoma by a Radio-neuro-endocrine Strategy with Radiotherapy Plus Melatonin Compared to Radiotherapy Alone, Lissoni, Meregalli, Nosetto, et al., Oncology 1996; 53: 43-46.

Five-Years Survival in Metastatic Non-Small Cell Lung Cancer Patients Treated with Chemotherapy Alone or Chemotherapy with Melatonin: A Randomized Trial, Lissoni, et al., J. Pineal Res. 2003; 35 (1): 12-15.

Circadian Function in Patients with Advanced Non-small-cell Lung Cancer, Levin, Daehler, Grutsch, et al., Br. J. Cancer 2005; 93 (11): 1202-1208.
Light at Night Co-distributes with Incident Breast But Not Lung Cancer in the Female Population of Israel, Kloog, Haim, Stevens, et al., Chronobiol. Int. 2008; 25 (1): 65-81.
Global Co-distribution of Light at Night (LAN) and Cancers of Prostate, Colon, and Lung in Men, Kloog , Haim, Stevens & Portnov,  Chronobiol. Int. 2009; 26 (1): 108-125. 

Aromatase Inhibitor-induced Joint Pain: Melatonin’s Role, Burk, Med. Hypoth. 2008; doi: 10.1016/j.mehy.2008.07.040.

Randomized Study with the Pineal Hormone Melatonin versus Supportive Care Alone in Advanced Non-small-cell Lung Cancer Resistant to a First-line Chemotherapy Containing Cisplatin, Lissoni, Barni, Ardizzoia, et al., Oncology 1992; 49 (5): 336-339.

An Overview of Melatonin and Breast Cancer, Kaczor, Nat. Med. J. 2010; 2 (2): 1-4.

Neuro-immunotherapy of Untreatable Metastatic Solid Tumors with Subcutaneous Low-dose Interleukin-2, Melatonin and Naltrexone: Modulation of interleukin-2-induced Anti-tumor Immunity by Blocking the Opioid System, Lissoni, Malugani, Malysheva, et al., Neuro. Endocrinol. Lett. 2002; 23 (4): 341-344.

Melatonin in Human Breast Cancer Tissue: Association with Nuclear Grade and Estrogen Receptor Status, Maestroni & Conti, Lab. Inv.1996; 75 (4): 557-561.

Immune and Endocrine Mechanisms of Advanced Cancer-Related Hypercortisolemia,  Lissoni, Brivio, Fumagalli, et al., In Vivo 2007; 21 (4): 647-650.

Melatonin Increase as Predictor for Tumor Objective Response to Chemotherapy in Advanced Cancer Patients, Lissoni, Tancini, Barni, et al., Tumori  1998; 74 (3): 339-345.

Chronotherapy for Cancer, Eriguchi, Levi, Hisa, et al., Biomed. Pharmacother. 2003; 57 Suppl 1: 92s-95s.

Biomodulation of Cancer Chemotherapy for Metastatic Colorectal Cancer: A Randomized Study of Weekly Low-dose Irinotecan Alone versus Irinotecan Plus the Oncostatic Pineal Hormone Melatonin in Metastatic Colorectal Cancer Patients Progressing on 5-fluorouracil-containing Combinations, Cerea, Vagh, Ardizzoia, et al., Anticancer Res. 2003; 23 (2C): 1951-1954.

Melatonin in Clinical Oncology, Bartsch, Bartsch & Karasek, Neuro. Endocrinol. Lett. 2002; 23 Suppl 1: 30-

Melatonin: Fifty Years of Scientific Journey from the Discovery in Bovine Pineal Gland to Delineation of Functions in Human, Chowdhury, Sengupta & Maitra, Indian J Biochem Biophys. 2008; 45 (5): 289-304.

The Immune-Pineal Axis: Stress as a Modulator of Pineal Gland Function, Couto-Moraes, Palermo-Neto & Markus, Ann N Y Acad Sci. 2009; 1153: 193-202. 

A Review of the Evidence Supporting Melatonin's Role as an Antioxidant, Reiter, Melchiorri, Sewerynek, et al., J Pineal Res. 1995; 18 (1): 1-11.
   
Health Disorders of Shift Workers, Knutsson, Occup Med (Lond). 2003; 53 (2): 103-108. 

Night-shift Work and Risk of Colorectal Cancer in the Nurses' Health Study, Schernhammer, Laden, Speizer, et al., J. Natl. Cancer Inst. 2003; 95 (11): 825-828.

Melatonin in the Treatment of Cancer: A Systematic Review of Randomized Controlled Trials and Meta-analysis, Mills, Wu, Seely & Guyatt, J. Pineal Res. 2005; 39 (4): 360-366.

Clinical Results with the Pineal Hormone Melatoninin in Advanced Cancer Resistant to Standard Antitumor Therapies, Lissoni, Barni, Meregalli, et al., Oncology 1991; 48: 448-450.

A Randomized Study of the Pineal Hormone Melatonin Versus Supportive Care Alone in Patients with Brain Metastases Due to Solid Neoplasms,  Lissoni, Barni, Ardizzoia, et al., Cancer 1994; 73: 69-701.
Aromatase Inhibitor-Induced Joint Pain: Melatonin's Role, Burk R. Med. Hypoth. 2008; Sep 7. [Epub ahead of print]

Extended Exposure to Dietary Melatonin Reduces Tumor Number and Size in Aged Male Mice, Sharman,  Sharman & Bondy, Exp. Gerontol. 2010 Sep 14. [Epub ahead of print] PMID: 20837128

Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival, Sephton, Sapolsky, Kraemer &Spiegel , J. Natl. Cancer. Inst.  2000; 92 (12): 994-1000.
Melatonin Modulates Aromatase Activity in MCF-7 Human Breast Cancer Cells, Cos, Martínez-Campa, Mediavilla &Sánchez-Barceló, J. Pineal Res. 2005; 38 (2): 136-142.

Pro-oxidant Effect of Melatonin in Tumour Leukocytes: Relation with its Cytotoxic and Pro-Apoptotic Effects, Bejarano, Espino, Barriga, et al., Basic Clin. Pharmacol. Toxicol. 2011; 108 (1): 14-20.

Melatonin Cytotoxicity in Human Leukemia Cells: Relation with its Pro-Oxidant Effect, Buyukavci, Ozdemir, Buck, et al., Fundam. Clin. Pharmacol. 2006; 20 (1): 73-79.
Modulation of Cancer Endocrine Therapy by Melatonin: A Phase II Study of Tamoxifen Plus Melatonin in Metastatic Breast Cancer Patients Progressing Under Tamoxifen Alone, Lissoni, Barni, Meregalli, et al., Br. J. Cancer 1995; 71 (4): 854-856.
Melatonin: From Basic Research to Cancer Treatment Clinics, Vijayalaxmi, Reiter & Herman, J. Clin. Oncol. 2002; 20 (10): 2575-2601.

A Phase II Study of Chemo-Neuro-Immunotherapy with Platinum, Subcutaneous Low-Dose Interleukin-2 and the Pineal Neuro-Hormone Melatonin (P.I.M. schedule) as a Second-Line Therapy in Metastatic Melanoma Patients Progressing on Dacarbazine Plus Interferon-Alpha, Lissoni, Vaghi & Ardizzoia, In Vivo 2002; 16 (2): 93-96.

Adjuvant Therapy With the Pineal Hormone Melatonin in Patients with Lymph Node Relapse Due To Malignant Melanoma, Lissoni, Brivio, Brivio, et al., J. Pineal Res. 1996; 21 (4): 239-242.

Melatonin Therapy of Advanced Human Malignant Melanoma, Gonzalez, Sanchez, Ferguson, et al., Melanoma Res. 1991; 1 (4): 237-243.

Reduction of Cisplatin-Induced Anemia by the Pineal Indole 5-MethoxyTryptamine in Metastatic Lung Cancer Patients, Lissoni, Malugani, Bukovec, et al., Neuro. Endocrinol. Lett. 2003; 24 (1-2): 83-85.
Selective Effect of Melatonin on the Proliferation of Lymphoid Cells, Persengiev & Kyurkchiev, Int. J. Biochem. 1993;25 (3): 441-444.
Melatonin: Reducing the Toxicity and Increasing the Efficacy of Drugs,  Reiter, Tan, Sainz , et al., J. Pharm. Pharmacol. 2002; 54 (10): 1299-1321.




MILK THISTLE
Toward the Definition of the Mechanism of Action of Silmarin: Activites Related to Cellular Protection from Toxic Damage Induced by Chemotherapy, Comelli, Mengs, Schneider, et al., Integr. Cancer Ther. 2007; 6 (2): 120-129.

Clinical Applications of Silybum Marianum in Oncology, Greenlee, Abascal, Yarnell, et al, Integr. Cancer Ther. 2007; 6 (2): 158-165.

Milk Thistle (Silybum marianum) is Associated with Reductions in Liver Function Tests (LFTs) in Children Undergoing Therapy for Acute Lymphoblastic Leukemia (ALL), Ladas, Cheng, Hughes, et al., Int. Conf. Soc. Integr. Oncol. 2006; abstract D045.

Antiproliferative Effect of Silybin on Gynaecological Malignancies: Synergism with Cisplatin and Doxorubicin, Scambia, DeVincenzo, Ranelletti, et al., Eur. J. Cancer  1996; 32 A (5): 877-882.

Silybin and its Bioavailable Phospholipid Complex (IdB 1016) Potentiate in vitro and in vivo the Activity of Cisplatin, Giacomelli, Gallo, Apollonio, et al, Life Sci. 2002; 70 (12): 1447-1459.

Effect of Silibinin on the Growth and Progression of Primary Lung Tumors in Mice, Singh, Deep, Chittezhath, et al., J. Natl. Cancer Inst. 2006; 98 (12): 846-855.

Advances in the Use of Milk Thistle, Post-White, Ladas & Kelly, Integr. Cancer Ther. 2007; 6 (2): 104-109.

A Randomized, Controlled, Double-blind, Pilot Study of Milk Thistle for the Treatment of Hepatotoxicity in Childhood Acute Lymphoblastic Leukemia (ALL),  Ladas, Kelly,et al., Cancer  2010; 116 (2): 506-513.

Milk thistle and Indinavir: A Randomized Controlled Pharmacokinetics Study and Meta-analysis, Mills, Wilson, Clarke, et al., Eur. J. Clin. Pharmacol. 2005; 61(1): 1-7.

Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irenotecan, van Erp, Baker, Zhao, et al., Clin. Cancer Res. 2005; 11 (21): 7800-7806.

Milk Thistle: Safe and Effective Around Chemotherapy? , Kerry Bone, Acupuncture Today December, 2010, Vol. 11, Issue 12.
Chemotherapeutic Activity of Silymarin Combined with Doxorubicin or Paclitaxel in Sensitive and Multidrug-Resistant Colon Cancer Cells, Colombo, Lupi, Falcetta, et al., Cancer Chemother. Pharmacol. 2010 Apr 30. [Epub ahead of print]
Silymarine During Maintenance Therapy of Acute Promyelocytic Leukemia, Invernizzi, Bernuzzi, Ciani, et al., Haematologica 1993;78 (5): 340-341.

Modulation of Human Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 Cell Monolayers by  Selected Commercial-Source Milk Thistle and Goldenseal Products, Budzinski, Trudeau, Drouin, et al., Can. J. Physiol. Pharmacol.  2007; 85 (9): 966–978. 
In Vivo Assessment of Botanical Supplementation on Human Cytochrome P450 Phenotypes: Citrus aurantium, Echinacea purpurea, Milk Thistle, and Saw Palmetto, Gurley, Gardner, Hubbard, et al., Clin. Pharmacol. Ther. 2004; 76 (5): 428-440.   Erratum in: Clin. Pharmacol. Ther. 2005; 77 (5): 456.

Effect of Milk Thistle (Silybum marianum) and Black Cohosh (Cimicifuga racemosa) Supplementation on Digoxin Pharmacokinetics in Humans, Fuhr, Beckmann-Knopp, Jetter, et al., Planta Med. 2007; 73 (14): 1429-1435.

Effect of Continuous Silymarin Administration on Oral Talinolol Pharmacokinetics in Healthy Volunteers, Han, Guo, Chen, at al., Xenobiotica 2009; 39, (9): 694-699.

Effect of Silymarin on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174 in Healthy Chinese Volunteers, Han, Guo, Chen, et al., Eur. J..Clin.Pharmacol. 2009; 65 (6): 585-591.
Effect of Silymarin Supplement on the Pharmacokinetics of Ornidazole in Healthy Volunteers, Repalle, Yamsani, Gannu, et al., Acta Pharma.Sci. 2009; 51 (1): 15-20.
Study on the Influence of Silymarin Pretreatment on Metabolism and Disposition of Metronidazole, Rajnarayana, Reddy, Vidyasagar & Krishna Arzneim-Forsch 2004; 54:109-113.
Silibinin Sensitizes Human Prostate Carcinoma DU145 Cells to Cisplatin- and Carboplatin-induced Growth Inhibition and Apoptotic Death, Dhanalakshmi, Agarwal, Glode & Agarwal, Int. J. Cancer 2003; 106 (5): 699-705.
 Anti-proliferative Effect of Silybin on Gynaecological Malignancies: Synergism with Cisplatin and Doxorubicin, Scambia, De Vincenzo, Ranelletti, et al., Eur. J. Cancer Part A 1996; 32: 877-882.

 Silibinin Restores Paclitaxel Sensitivity to Paclitaxel-resistant Human Ovarian Carcinoma Cells, Zhou, Liu, Chen, et al., Anticancer Res. 2008; 28 (2A): 1119-1127.

Oral Silibinin Inhibits Lung Tumor Growth in Athymic Nude Mice and Forms a Novel Chemocombination with Doxorubicin Targeting Nuclear Factor kappa B-Mediated Inducible Chemoresistance, Singh, Mallikarjuna, Sharma, et al.,  Clin. Cancer Res. 2004; 10 (24): 8641-8647.

Antimetastatic Efficacy of Silibinin: Molecular Mechanisms and Therapeutic Potential Against Cancer, Deep & Agarwal, Cancer Metastasis Rev. 2010; 29 (3): 447-463.


MISTLETOE LECTINS
Differential Effects of Viscum album Extract Iscador Qu on Cell Cycle Progression and Apoptosis in Cancer Cells, Harmsma, Gromme, Ummelin, et. al., Int. J. Oncol. 2004; 25: 1521 – 1529.

Impact of Complementary Mistletoe Extract Treatment on Quality of Life in Breast, Ovarian and Non-Small Cell Lung Cancer Patients. A Prospective, Randomized Controlled Clinical Trial, Piao, Wang, Xie, et al.  Anticancer Res.  2004; 34: 303-309.

Use of Iscador, an Extract of European Mistletoe (Viscum album) in Cancer Treatment: Prospective Non-Randomized and Randomized Matched-Pair Studies Nested Within a Cohort Study, Grossarth-Maticek, Kiene, Baumgartner & Ziegler  Alt. Ther.  2001; Vol. 7 No. 3: 57-78.

Treatment of Advanced Pancreatic Cancer with Mistletoe: Results of a Pilot Trial Friesse, et al. 1996; Anticancer Res. 16 : 915-920.

Mistletoe Extract May Be Alternative Bladder Cancer Therapy, Elsaesser-Beile, et al. July 2005;  J. Urol. 174: 176-179.

Final Results of the EORTC 18871 / DKG 80-1 Randomised Phase III Trial: rIFN-alpha2b vs. rIGN-gamma vs. Iscador M vs. Observation After Surgery in Melanoma Patients with Either High-risk Primary or Regional Lymph Node Metastasis, Kleeberg, Suciu, Brocker, et al., Eur. J. Cancer 2004; 40: 390-402.

Safety and Efficacy of the Long-term Treatment of Primary Intermediate to High-risk Malignant Melanoma (UICC/AJCC stage II and III) with a Standardized Fermented European Mistletoe Extract: Results from a Multicenter, Comparative, Epidemiological Cohort Study in Germany and Switzerland, Augustin, Bock, Hanisch, et. al., Arzeimittelforschung, 2005; 55 (1):38-49.

Anti-proliferative Effect of Iscador Against Urinary Bladder Carcinoma, Urech, et al., Anti-Cancer Res. 2006; 26: 3049-3056.

Nitric-Oxide Involvement in the Anti-Tumor Effect of Mistletoe ( Viscum album L. ) Extract Iscador on Human Macrophages, Mossalayi, Alkharrat & Malvy, Arzneimittelforschung  2006; 56 (6A): 457-460.

Iscador Qu Spezial Inhibits Tube Formation, Elluru, et al, Drug Res., 2006; 56: 461.

Palliative In-Patient Cancer Treatment in an Anthroposophic Hospital: II. Quality of Life During and After Stationary Treatment, and  Subjective Treatment Benefits, Heusser, Braun, Burtschy et al., Forsch Komplementarmed, 2006; 13: parts I & II.

Iscador in Breast Cancer (I), Leroi, Helvet Chir Acta 1977; 44.

Iscador in Breast Cancer (II), Hellan, et. al., Krebs und Alternativ-Medizin II, 1990, Springer.

Iscador in Breast Cancer (III), Grossarth-Maticek, et. al., Altern. Ther. Health Med., 2001; 7.

Iscador in Breast Cancer (IV), Grossarth-Maticek, et. al., Altern. Ther. Health Med., 2001; 7.

Iscador in Breast Cancer (V), Bock et. al., Drug Res. 2004; 58.

Iscador in Cancer of Different Locations, Grossarth-Maticek, et. al., Altern. Ther. Health Med., 2001; 7: 3.

Efficacy and Safety of Long-term Complementary Treatment with Standardized European Mistletoe Extract
(Viscum albu. L.) in Addition to the Conventional Adjuvant Oncological Therapy in Patients with Primary Non-metastatic Breast Cancer – Results of a Multicentre, Comparative, Epidemiological Cohort Study, Bock, Friedel, Hanisch et. al., Arneim-Forsch/ Drug Res. 2004; 54 No. 8: 456 – 466.

Anticancer Activity of a Lectin-Rich Mistletoe Extract Injected Intratumorally into Human Pancreatic Cancer Xenografts,  Rostock, Huber, Greiner, et al., Anticancer Res  2005; 25 (3B): 1969-1975.

Reducing Malignant Ascites Accumulation by Repeated Intraperitoneal Administrations of a Viscum album Extract, Bar-Sela, Goldberg, Beck, et al., Anticancer Res.  2006; 26 (1B): 709-713.

Quality of Life is Improved in Breast Cancer Patients by Standardized Mistletoe extract PS76A2 During Chemotherapy and Follow-up: a Randomised, Placebo-controlled, Double-Blind, Multicentre Clinical Trial,
Semiglazov, Stepula, Dudov, et al., Anticancer Res. 2006; 26 (2B): 1519-1529.

Immunological Effector Mechanisms of a Standardized Mistletoe Extract On the Function of Human Monocytes and Lymphocytes in vitro, ex vivo and in vivo, Heinzerling, von Baehr, Liebenthal, et al., J. Clin. Immunol. 2006; 26 (4): 347-359.

Anticancer Activity of a Lectin-rich Mistletoe Extract Injected Intratumorally into Human Pancreatic Cancer Xenografts,  Rostock, Huber, Greiner, et al., Anticancer Res  2005; 25 (3B): 1969-1975.

Prospective Controlled Cohort Studies on Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador(r), Grossarth-Maticek & Ziegler, Forsch Komplementarmed 2006; 13 (5): 285-292.

Immune Modulation Using Mistletoe (Viscum album L.) Extracts Iscador, Büssing, Arzneimittelforschung 2006; 56 (6A): 508-515.

Anti-proliferative Effects of Mistletoe (Viscum album L.) Extract in Urinary Bladder Carcinoma Cell Lines, Urech, Buessing, Thalmann, et al., Anticancer Res. 2006; 26 (4B): 3049-3055.

Mistletoe for Cancer? A Systematic Review of Randomised Clinical Trials, Ernst, Schmidt & Steuer-Vogt, Int. J. Cancer 2003; 107 (2): 262-267.

Complementary Cancer Therapy: A Systematic Review of Prospective Clinical Trials on Anthroposophic Mistletoe Extracts, Kienle & Kiene, Eur. J. Med. Res. 2007; 12 (3): 103-119

Mistletoe Therapy in Oncology, Horneber, Bueschel, Huber R, et al.,Cochrane Database Syst. Rev. 2008; (2): CD003297.

Survival of Cancer Patients Treated with Mistletoe Extract (Iscador): A Systematic Literature Review, Ostermann, Raak & Bussing, BMC Cancer 2009; 9 (1): 451.

Viscum album L. Extracts in Breast and Gynaecological Cancers: A Systematic Review of Clinical and Preclinical Research, Kienle, Glockmann, Schink & Kiene, J. Exp. Clin. Cancer Res. 2009; 28: 79.

Systematic Evaluation of the Clinical Effects of Supportive Mistletoe Treatment within Chemo-and/or Radiotherapy Protocols and long-Term Mistletoe Application in Nonmetastatic Colorectal Carcinoma: Multicenter, Controlled, Observational Cohort Study, Friedel, Matthes, Bock & Zanker, J. Soc. Integr. Oncol.
2009; 7 (4): 137-145.

Influence of Viscum album L. (European Mistletoe) Extracts on Quality of Life in Cancer Patients: A Systematic Review of Controlled Clinical Studies, Kienle & Kienle, Integr. Cancer Ther. 2010; 9 (2): 142-157.

Viscum Album Extracts Iscador® P and Iscador® M Counteract the Growth Factor Induced Effects in Human Follicular B – NHL Cells and Breast Cancer Cells, Hugo, Schwitalla, Niggemann, et al., Medicina 2007; 67 (Suppl. II): 90-96.


MITOCHONDRIA
Mitochondria and Cancer, Jurasunas, Townsend Letter 2006; # 277/78: 83-86, 146-148.

The Role of Mitochondria in Glioma Pathophysiology, Orbys, Launay, Deighton, et al., Mol. Neurobiol. 2010; 42 (1): 64-75.

The Causes of Cancer Revisited: ``Mitochondrial Malignancy`` and ROS-Induced Oncogenic Transformation - Why Mitochondria are Targets for Cancer Therapy, Ralph, Rodriguez-Enriquez, Neuzil, et al., Mol. Aspects Med. 2010; 31 (2): 145-170.

Cancer Cell Mitochondria Confer Apoptosis Resistance and Promote Metastasis, Kulawiec, Owens & Singh, Cancer Biol. Ther. 2009; 8 (14): 1378-1385.

ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis, Ishikawa, Takenaga, Akimoto, et al., Science 2008; 320 (5876): 661-664.

Somatic Mutations in Mitochondrial Genome and Their Potential Roles in the Progression of Human Gastic Cancer, Hung, Wu, Yin, et al., Biochem. Biophys. Acta 2010; 1800 (3): 264-270.

Positive Contributions of Pathogenic Mutations in the Mitochondrial Genome to the Promotion of Cancer by Prevention of Apoptosis, Shigara, Yamagata, Kanamori, et al., Cancer Res. 2005; 65 (5): 1655-1663.

Mitochondrial Dysfunction is a Common Phenotype in Aging and Cancer, Singh, Ann. NY Acad. Sci. 2004; 1019: 260-264.

Mitochondria-Targeted Antioxidants in the Treatment of Disease, Smith, Adlam, Blaikie, et al., Ann. NY Acad. Sci. 2008; 1147: 105-111.

A Mitochondria-K+ Channel Axis is Suppressed in Cancer and its Normalization Promotes Apoptosis & Inhibits Cancer Growth, Bonnet, Archer, Allalunis-Turner, et al., Cancer Cell 2007; 11 (1): 37-51.     PubMed ID# 17222789

The Biological Significance of Cancer: Mitochondria as a Cause of Cancer and the Inhibition of Glycolysis with Citrate as a Cancer Treatment, Halabe Bucay, Med Hypotheses  2007; 69 (4): 826-828.

Cheap, Safe Drug Kills Most Cancers, Coghlan, New Scientist January 2007.

Metabolic Interactions of Dichloroacetate and Insulin in Experimental Diabetic Ketoacidosis, Backshear, Holloway & Alberti, Chem. Res. Toxicol. 2000;13 (4): 2312-236.

Trial of Dichloroacetate in MELAS: Toxicity Overshadows the Assessment of Potential Benefit, Schaefer, Neurology 2006; 66 (3): 302-303. 

Dichloroacetate Causes Toxic Neuropathy in MELAS: A Randomized Controlled Clinical Trial, Kaufmann, Engelstad, Wei, et al., Neurology 2006; 66 (3): 324-330.

Clinical Pharmacology and Toxicology of Dichloroacetate, Stacpoole, Henderson, Yan & James, Envir. Health Perspect. 1998; 106 (Suppl. 4): 989-994.

Treatment of Symptomatic Diabetic Polyneuropathy with the Antioxidant  α-Lipoic Acid.  A 7-Month Multicenter Randomized Controlled Trial (ALA-DIN III Study),  Ziegler, Hanefeld, Ruhnau, et al., Diabetes Care 1999; 22: 1296-1301.

Prevention of Incipient Diabetic Nephropathy by High-Dose Thiamine and Benfotaimine, Babaei-Jadidi, Karachalias, Ahmed, et al., Diabetes 2003; 52: 2110-2120.

Effects of Dichloroacetate and Ubiquinone Infusions on Glycolysis Activity and Thermal Sensitivity During Sepsis, L'Her & Sebert,  J. Lab. Clin. Med. 2004; 143 (6): 352-357

Dichloroacetate Causes Reversible Demyelination In Vitro: Potential Mechanism for Its Neuropathic Effect, Felitsyn, Stacpoole & Notterpek, J. Neurochem. 2007; 100 (2): 429-436.

Metabolic Modulation of Glioblastoma with Dichloroacetate, Michelkakis, et al., Sci. Transl. Med. 2 2010; 31ra34: DOI: 10.1126/scitranslmed.3000677.

Use of Oral Dicholoracetate for Palliation of Leg Pain Arising from Metastatic Poorly Differentiated
Carcinoma: A Case Report, Khan, J.Palliat. Med. 2011; 14 (5): 

Sodium Dichloroacetate (DCA) Reduces Apoptosis in Colorectal Tumor Hypoxia, Shahrzad, Lacombe, Adamcic, et al., Cancer Lett. 2010; 297 (1):75-83.

Pangamic Acid (“Vitamin B15”), Victor Herbert, Amer. J. Clin. Nutr. 1979; 32: 1534-1540.

Restoration of Cellular Energetic Balance with L-Carnitine in the Neuro-bioenergetic Approach for Cancer Prevention and Treatment, Hoang, Shaw, Pham & Levine, Med. Hypotheses 2007; 69 (2): 262-272.

Increased Carnitine-dependent Fatty Acid Uptake into Mitochondria of Human Colon Cancer Cells Induces Apoptosis, Wenzel, Nickel & Daniel, J. Nutr. 2005; 135 (6): 1510-1514.

Carnitine Supplementation Alleviates Cancer-Related Fatigue, Cruciani, et al., J. Pain Sympt. Man.  2006; 32: 551-559.

Voltage-Dependent Anion Channel (VDAC) as Mitochondrial Governator – Thinking Outside the Box, Lemasters & Holmuhamedov, Biochem.Biophys. Acta 2006; 1762 (2): 181-190.

Lactate: Mirror and Motor of Tumor Malignancy, Walenta & Mueller-Klieser ,Semin Radiat Oncol. 2004; 14 (3): 267-74.

High Lactate Levels Predict Likelihood of Metastases, Tumor Recurrence, and Restricted Patient Survival in Human Cervical Cancers, Walenta, Wetterling, Lehrke, et al., Cancer Res. 2000; 60 (4): 916-921.

Tumor-derived Lactic Acid Modulates Dendritic Cell Activation and Antigen Expression, Gottfried, Kunz-Schughart, Ebner, et al., Blood. 2006; 107 (5): 2013-2021.

Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association with Survival and Activated Vascular Endothelial Growth Factor Pathway - A Report of the Tumour Angiogenesis Research Group, Koukourakis, Giatromanolaki, Sivridis, et al., J Clin Oncol. 2006; 24 (26): 4301-4308.

Lactate Dehydrogenase 5 (LDH5) Relates to Up-regulated Hypoxia Inducible Factor Pathway and Metastasis in Colorectal Cancer, Koukourakis, Giatromanolaki, Simopoulos, et al., Clin Exp Metastasis 2005; 22( 1): 25-30.

Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1, Luo, Hu, Chang, et al., Cell 2011; 145 (5):  732-744.

Studies with Glycolysis-Deficient Cells Suggest that Production of Lactic Acid is Not the Only Cause of Tumor Acidity,  Newell, Franchi, Pouysségur & Tannock,  Proc Natl Acad Sci U S A. 1993; 90 (3): 1127-1131.

Early and Late Apoptosis Events in Human Transformed and Non-transformed Colonocytes are Independent of Intracellular Acidification,  Wenzel & Daniel, Cell Physiol Biochem. 2004;14 (1-2): 65-76.

Mitochondria and Cancer: Warburg Addressed, Wallace, Cold Spring Harb. Symp. Quant. Biol. 2005; 70: 363-374.

Cu2+ Toxicity Inhibition of Mitochondrial Dehydrogenases in vitro and in vivo, Sheline & Choi,  Ann. Neurol. 2004; 55 (5): 645-653.

Cofactors of Mitochondrial Enzymes Attenuate Copper-induced Death in vitro and in vivo, Sheline, Choi, Kim-Han, et al.,  Ann Neurol.  2002; 52 (2): 195-204.

Effect of Thiamine Phosphates on the Activity of Regulatory Enzymes of the Pyruvate Dehydrogenase Complex,  Parkhomenko, Chernysh, Cjurilova, et. al., Ukr. Biokhim. Zh. 1987; 59 (5): 49-54.

Bovine Heart Pyruvate Dehydrogenase Kinase Stimulation by Alpha-ketoisovalerate, Robertson, Barron & Olson, J. Biol. Chem.  1990; 265 (28): 16814-16820.

Co-enzyme Q10 Improves Lactic Acidosis, Stroke-like Episodes and Epilepsy in a Patient with MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-like Episodes), Berbel-Gacia, Barbera-Farre, Etessam, et al., Clin. Neuropharmacol.  2004; 27 (4): 187-191.

Mitochondria Rescue (Possibly) Heals Cancer? , McKinney, Naturopathic Doctor News & Review - May 2008; 4 (5): 10-11.

Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid, Fulda, Scaffidi, Susin, et al., J. Biol. Chem. 1998; 18: 273 (51): 33942-33948.

Pharmacological  Effects On Mitochondrial Function, Cohen, Develop. Disab. Res. Rev. 2010; 16: 189-199.

On-Target Inhibition of Tumor Fermentative Glycolysis as Visualized by Hyperpolarized Pyruvate, Seth, Grant, Tang, et al., Neoplasia 2011; 13 (1): 60-71.

The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes, Levine, Puzio-Kuter, Science 2010; 330 (6009): 1340-1344.

Mitochondria in Cancer: Not Just Innocent Bystanders, Frezza & Gottlieb, Sem. Cancer Biol. 2009; 19: 4-11.


MODIFIED  CITRUS  PECTIN
The Potential Role of Modified Citrus Pectin in the Prevention of Cancer Metastasis, Eliaz, Clin. Pract. Altern. Med. 2001; 2 (3): 177-179.

Galectin-3 as a Potential Target in Tumors Arising from Malignant Epithelia, Johnson, Glinskii, et al.,  Neoplasia 2007; 9 (8): 662-670.

Modified Citrus Pectin Slows PSA Doubling Time: A Pilot Clinical Trial,  Strum, et al., Int. Conf. on Diet & Prev. Cancer 1999.

Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin, Platt & Raz, J. Natl. Cancer Inst. 1992; 84 (6): 438-442.

Citrus Pectin: Characterization and Inhibitory Effect on Fibroblast Growth Factor- Receptor Interaction, Liu, Ahmad, Luo, et. al., J. Agric. Food Chem. 2001, 49 (6): 3051-3057.

Inhibition of Spontaneous Metastasis in a Rat Prostate Cancer Model by Oral Administration of Modified Citrus Pectin, Pienta, Naik, Akhtar, et. al, J. Natl. Cancer Inst. 1995; 87 (5): 348-353.

Inhibition of  Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin, Nangia-Makker, Pratima, Hogan, et al., J. Natl. Cancer Inst. 2002; 94 (24): 1854-1862.

Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis, Nangia-Makker, Honjo, Sarvis, et. al., Am. J. Pathol. 2000, 156 (3): 899-909.

Recognition of Galactan Components of Pectin by Galectin-3, Gunning, Bongaerts & Morris, Fed. Amer. Soc. Exp. Biol. J.  2008; 10.1096: fj. O8-106617.

PectaSol-C Modified Citrus Pectin Induces Apoptosis and Inhibition of Proliferation in Human and Mouse Androgen-Dependent and - Independent Prostate Cancer Cells, Yan & Katz, Integr. Cancer Ther. 2010; 9: 197-203.

Modified Citrus Pectin Enhances the Effect of Novel Dietary Supplement Formulas Inhibition of Invasiveness of Breast and Prostate Cancer Cells by Down-regulation of Urokinase Plasminogen Activator (uPA) Secretion,  Wojnowski, Jaing, Jedinak & Sliva, Experimental Biology 2010, Anaheim, CA, April, 2010. (FASEB J. 24: 207.4)

Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study, Azemar, Hildenbrand, Haering, et al., Clin. Med. Oncol. 2007; 1: 173-180.

Modified Citrus Pectin(MCP) Increases the Prostate-specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study, Guess, Scholz, Strum, et al., Prostate Cancer Prostatic Dis. 2003; 6 (4): 301-304.

Effects of Daily Oral Administration of Quercitin Chalcone and Modified Citrus Pectin on Implanted Colon-25 Tumor Growth in Balb-c Mice, Hayashi, Gillen & Lott, Altern. Med. Rev. 2000; 5 (6): 546-552.

Changes in Cell Growth, Cyclin/Kinase, Endogenous Phosphoproteins and nm23 Gene Expression in Human Prostatic JCA-1 Cells Treated with Modified Citrus Pectin, Hsieh & Wu,  Biochem. Mol. Biol. Int. 1995; 37 (5): 833-841.

Effects of Natural Complex Carbohydrate (Citrus Pectin) on Murine Melanoma Cell Properties Related to Galectin-3 Functions, Inohara & Raz, Glycoconj. J. 1994; 11 (6): 527-532.

Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin, Nangia-Makker, Hogan, Honjo, et al., J. Natl. Cancer Inst. 2002; 94 (24): 1854-1862.
Inhibition of in vitro Tumor Cell-Endothelial Adhesion by Modified Citrus Pectin: A pH Modified Natural Complex Carbohydrate, Naik, Pilat & Donat, Proc. Am. Assoc. Cancer Res. 1995; 36: A377.       

MUSHROOMS (Reishi, button mushrooms, etc.)
Anti-Aromatase Activity of Phytochemicals in White Button Mushrooms (Agaricus bisporus), Chen, Oh, Phung, et al., Cancer Res.  2006; 66 (24): 12026-12034.

White Button Mushroom Phytochemicals Inhibit Aromatase Activity and Breast Cancer Cell Proliferation, Grube, Eng, Kao, et al., J. Nutr. 2001; 131 (12): 3288-3293.

Novel Antioxidant Peptides from Fermented Mushroom Ganoderma lucidum, Sun, He & Xie,  J. Agric. Food Chem. 2004; 52 (21): 6646-6652.

Ganodermic Acid T from Ganoderma lucidum Mycelia induces Mitochondria Mediated Apoptosis in Lung Cancer Cells, Tang, Liu, Zhao, et al., Life Sci. 2006; 80 (3): 205-211.

Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells by Ganoderma lucidum and Duchesnea chrysantha extracts, Kim, Kim, Son & Kim, Cancer Lett. 2007; 246 (1-2): 210-217.

Coriolus versicolor (Yunzhi) Extract Attenuates Growth of Human Leukemia Xenografts and Induces Apoptosis Through the Mitochondrial Pathway, Zhang, Soboloff, Zhu & Berger, Mol. Pharmacol. 2006; 16 (3): 609-616.

Ganoderma lucidum Inhibits Proliferation of Human Breast Cancer Cells by Down-regulation of Estrogen Receptor and NF-kappaB Signalling, Jiang, Slivova & Sliva, Int. J. Oncol. 2006; 29 (3): 695-703.

Tidak ada komentar:

Posting Komentar